Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 66030249 | 6603024 | 9 | F | 20080312 | 20160822 | 20080401 | 20160822 | EXP | BE-BRISTOL-MYERS SQUIBB COMPANY-14129050 | BRISTOL MYERS SQUIBB | 39.86 | YR | F | Y | 66.50000 | KG | 20160822 | CN | US | BE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 66030249 | 6603024 | 1 | PS | REYATAZ | ATAZANAVIR SULFATE | 1 | Oral | 2 DF, QD | 21567 | 2 | DF | CAPSULE, HARD | QD | ||||||
| 66030249 | 6603024 | 2 | SS | COMBIVIR | LAMIVUDINEIDOVUDINE | 1 | Oral | 1 DF, BID | 0 | 1 | DF | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 66030249 | 6603024 | 1 | Acquired immunodeficiency syndrome |
| 66030249 | 6603024 | 2 | Acquired immunodeficiency syndrome |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 66030249 | 6603024 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 66030249 | 6603024 | Abortion induced | |
| 66030249 | 6603024 | Pregnancy |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 66030249 | 6603024 | 1 | 20040922 | 0 | ||
| 66030249 | 6603024 | 2 | 20040922 | 0 |